

suisselle   
beauty ■ science ■ innovation

CHAC technology  
CELLBOOSTER®  
HAIR



## CLINICAL TRIAL

Results of the clinical trial on 26 healthy subjects treated with CELLBOOSTER® HAIR  
(stabilized booster complex using CHAC technology).

Fighting hair loss & Strengthening hair follicles to improve hair density and quality

## CLINICAL TRIAL

### INDICATIONS:

- Non cicatricial alopecia,
- Alopecia areata,
- Androgenic alopecia,
- Damaged hair shaft (brittle, dull color, split ends),
- Premature graying,
- Seborrhea, psoriasis.

- ✓ Nourishes the scalp and fortifies follicles,
- ✓ Accelerates hair growth,
- ✓ Prevents hair loss and graying.

### TREATMENT AREAS:

Epidermis and dermis of the scalp (near hair roots according to the mesotherapy applied technique).

### COMPOSITION:

HYALURONIC ACID 18 mg

#### VITAMINS

- Niacin
- Pantothenic Acid (B5)
- Pyridoxine (B6)
- Biotin (B7)
- Cyanocobalamin (B12)
- Rutin



**STABILIZED REJUVENATING COMPLEX**  
 CHAC technology

#### AMINO ACIDS

- Arginine
- Cysteine
- Glutamine
- Glycine
- Lysine

#### COPPER


#### ZINC

### METHODOLOGY:

#### Study purpose:

The objective of this study was to clinically assess the effect on hair density and hair quality after 6 sessions of CELLBOOSTER® HAIR injections on 26 healthy subjects, equally shared between men and women.

#### Patient treatments and follow-up & assessments



### ASSESSMENTS:

#### Hair quality clinical analysis:

- ✓ Thickness
- ✓ Shine
- ✓ Hair loss

#### Hair density & thickness improvement:

- ✓ Scoring on macrophotography with Proscope x30

#### Hair shine

- ✓ Measurement with GlossyMeter

#### Effect of the product:

- ✓ Scalp photographs by LifeViz 2D mini®

#### Subject satisfaction (self assessment) and GAIS (global aesthetic improvement scale)

#### Tolerance:

- ✓ Check of the absence of undesirable events at each visit.
- ✓ Each adverse event was reported within 48 hours and was included in the study report.

## CLINICAL TRIAL

### INCLUSION CRITERIA


#### General criteria:

- ✓ Subjects able to follow the trial procedures.
- ✓ Subjects giving their free and written consent after oral and written information about the study.

#### Specific criteria:


- ✓ Women or men, age over 18 years old.
- ✓ For men, qualification by the Norwood-Hamilton scale: class 2a, 3, 3a or 3a vertex.

#### Norwood-Hamilton scale



- ✓ For women, qualification by the Ludwig scale: type 1 or 2

#### Ludwig scale



- ✓ Women agreed to perform a pregnancy test (for women who can procreate a pregnancy test will be performed before each injection).
- ✓ Low to moderate capillary density.
- ✓ Subject not using care (topical or systemic) intended for hair growth/improvement.
- ✓ Subject agreeing not to be exposed to the sun for the duration of the study.

### PRINCIPAL EXCLUSION CRITERIA - SUBJECTS WITH:

#### General criteria:

- ✓ Currently participating in another clinical study related to pharmaceuticals or medical devices or subject in a period of exclusion from a clinical study.
- ✓ Facial injections/implants of any non-absorbable filler in his or her lifetime.
- ✓ Pregnant or lactating woman.
- ✓ Often exposed to the sun or UV during the last 15 days.

#### Allergies & inflammatory condition or other risk of infections:

- ✓ History of multiple severe allergies or anaphylactic shock.
- ✓ Known hypersensitivity to hyaluronic acid or to chlorhexidine.
- ✓ Tendency to develop inflammatory skin reactions or hypertrophic scars.
- ✓ An inflammatory skin reaction on or near the area to be treated (according to the opinion of the investigator).
- ✓ History of streptococcal disease (recurrent angina, rheumatic fever).
- ✓ Skin pathology, or an acute inflammatory reaction or bacterial or viral infection, at the study area level, or seen 6 weeks after the end of such an episode.
- ✓ Epilepsy not controlled by treatment.
- ✓ General pathology, skin pathology, dermatosis, acute or chronic systemic disease, and/or taking general or topical treatment that in the opinion of the investigator may interfere with the treatment or compromise the subject's participation in the study.
- ✓ Dermatological diseases that can reach the scalp (for example: pelade or lichen planus).
- ✓ Endocrine disruption mainly affecting the thyroid and more specifically hypothyroidism.

#### Concomitant treatments:


- ✓ Oral/injectable corticosteroid (or not stopped for ≥ 3 months). Inhaled corticosteroids are allowed as well as topical corticosteroid therapy not involving study areas.
- ✓ Concomitant treatment (or not stopped for ≥ 1 year) of immunosuppressant or chemotherapy - A history of less than 12 months of radiation therapy at the study area level or of autoimmune pathology or connective tissue.
- ✓ Aspirin or anti-coagulants in regular doses during the past 15 days.

**CLINICAL EVALUATION RESULTS**  
 3 weeks after the injection protocol (6 treatments)

**CELLBOOSTER® Hair:**  
 for more hair strenght  
 and resistance




Clinical evaluation



**CELLBOOSTER® Hair:**  
 for significantly less  
 loss




Clinical evaluation



**CELLBOOSTER® Hair:**  
 for shiny hair



Clinical evaluation




\* Not significant  
 Statistical analyses were performed with the Friedman test.

**BIOMETRIC EVALUATION RESULTS**  
 3 weeks after the injection protocol (6 treatments)

**CELLBOOSTER® Hair:**  
 a confirmation of the  
 improvement of hair  
 thickness by Proscope  
 X30




Macrophotography



**CELLBOOSTER® Hair:**  
 for more density




Macrophotography (Proscope X30)



**CELLBOOSTER® Hair:**  
 a confirmation of the  
 improvement of hair  
 shine by glossymeter



Biometric assessment (glossymeter)



\* Not significant  
 Statistical analyses were performed with the Friedman test.

CHAC technology  
**CELLBOOSTER®**  
**HAIR**

A very high satisfaction of the subjects regarding the benefits of CELLBOOSTER® Hair

**96%**  
 "MY HAIR CONDITION IS GLOBALLY IMPROVED"

**88%**  
 "MY HAIR LOSS IS REDUCED"

**88%**  
 "MY HAIR IS DENSER"

**84%**  
 "MY HAIR IS THICKER"

**77%**  
 "MY HAIR IS SHINIER"

**65%**  
 "MY HAIR GROWTHS BACK FASTER"

*\*(% of patients who "completely agree" or "rather agree" on quality of their hair – answer gathered with a self questionnaire)*

D0

D90



D0

D90





D0

D90



D0

D90





D0

D90




D0

D90




D40

D90



D0

D90



**88%**  
 "I WOULD RECOMMEND THE TREATMENT TO MY FRIENDS"

CHAC technology  
**CELLBOOSTER®**  
**HAIR**

## CONCLUSION

Results 3 weeks after the injection protocol (6 treatments)

A strong clinical trial that allows 3 weeks after a 6 injections protocol to observe that CELLBOOSTER® Hair leads to:

A very high patient satisfaction

### Clinical evaluation

### Biometric assessments

**+37.5%**  
THICKNESS

**+9.4%**  
THICKNESS

**-54.9%**  
LOSS

**+26%**  
DENSITY

**+32.6%**  
SHINE

**+38.7%**  
SHINE



**9**  
PATIENTS  
OUT OF 10

Found their hair at least improved to very much improved.

**+88.4%** Find an improvement of the hair density.

**+88.6%** Find a slow down in hair loss.

**+84.7%** Find their hair thicker.

With a dermatological tolerance that was judged by the investigators as being **Excellent for the 26 patients.**

# suisselle


beauty ■ science ■ innovation



Rue Galilée 6 | 1400 Yverdon-les-Bains | Switzerland

[www.suisselle.com](http://www.suisselle.com) | [info@suisselle.com](mailto:info@suisselle.com)

 Suisselle Global

 @suisselle.pro